Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. JAMA Dermatol. 2020 12 01; 156(12):1344-1353.

View in: PubMed

subject areas

Adult
Antibodies, Monoclonal
Double-Blind Method
Female
Humans
Maintenance Chemotherapy
Male
Middle Aged
Patient Reported Outcome Measures
Psoriasis
Quality of Life
Severity of Illness Index
Treatment Outcome
Ustekinumab

authors with profiles

Kenneth Gordon